Bruce Cuthbert, PhD, the head of the NIMH’s new Research Domain Criteria (RDoC) program, explains how this new way of funding and conducting research in psychiatry is revolutionizing the field.
Read More
Concerns about the safety of psychiatric medications during pregnancy are common among psychiatrists and patients alike. In many cases, one must weigh the risks of a medication to mother or child against the risks inherent in untreated mental illness. Recent research, however, lends support to the growing data about the safety of antidepressant medications in pregnancy.
Read More
It’s important to understand what bias is not. Bias is not fraud, as it does not involve intentional prejudice. Bias is also not random error, which creates deviation in results strictly by chance, and can be mitigated with a large enough study sample. Put simply, bias has to do with the unintentional skewing of results due to human failings such as poor trial design or unconscious wishes for desirable outcomes.
Read More
After a psychiatric drug is approved by the Food and Drug Administration (FDA), a marketing juggernaut often follows, trying to convince us that the newly approved drug offers substantial benefits for treating a mental disorder. But how does the FDA determine whether to approve a drug? What follows is a breakdown of the process.
Read More
Dr. Aiken is the Editor in Chief of The Carlat Psychiatry Report; director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments; and Assistant Professor NYU Langone Department of Psychiatry. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice. Follow him on Twitter and find him on LinkedIn.